- Home
- ATHA
ATHA
Athira Pharma Inc.
as 01-17-2025 4:00pm EST
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 21.0M | IPO Year: | 2020 |
| Target Price: | $11.25 | AVG Volume (30 days): | 235.4K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.41 - $4.30 | Next Earning Date: | 02-20-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Athira Pharma Inc. (ATHA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| San Martin Javier | ATHA | CHIEF MEDICAL OFFICER | Dec 31 '24 | Sell | $0.56 | 10,826 | $6,083.13 | 35,841 | |
| Litton Mark James | ATHA | President and CEO | Dec 31 '24 | Sell | $0.56 | 25,107 | $14,107.62 | 242,591 | |
| Worthington Mark | ATHA | General Counsel and CCO | Dec 31 '24 | Sell | $0.56 | 8,510 | $4,781.77 | 83,735 | |
| CHURCH KEVIN | ATHA | CHIEF SCIENTIFIC OFFICER | Dec 31 '24 | Sell | $0.56 | 8,510 | $4,781.77 | 130,761 | |
| Renninger Robert | ATHA | VP of Finance | Dec 31 '24 | Sell | $0.56 | 2,881 | $1,618.83 | 89,724 |
Latest Athira Pharma Inc. News
ATHA Breaking Stock News: Dive into ATHA Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Athira Pharma Insider Ups Holding By 111% During Year
GlobeNewswire
a month ago
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
BioPharma Dive
2 months ago
Athira exploring strategic alternatives after Alzheimer’s failure
GlobeNewswire
2 months ago
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Simply Wall St.
2 months ago
US Penny Stocks: November 2024's Top Picks To Consider
GlobeNewswire
3 months ago
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
GlobeNewswire
4 months ago
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
Zacks
4 months ago
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
Compare ATHA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATHA Athira Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.